NUCLEAR MEDICINE AND ONCOLOGY 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 June;48(2):143-9

Copyright © 2009 EDIZIONI MINERVA MEDICA

lingua: Inglese

Ovarian cancer management. Practice guidelines for nuclear physicians

Classe J. M. ¹, Fontanelli R. ², Bischof-Delaloye A. ³, Chatal J. F. ⁴

¹ Surgical Department, Centre René Gauducheau Nantes Saint Herblain, France 2 Division of Gynecological Oncology Surgery Istituto Nazionale Tumori, Milan, Italy 3 Nuclear Medicine Division PET Center, Istituto Nazionale Tumori, Milan, Italy 4 Nuclear Medicine Department, Centre René Gauducheau Nantes Saint Herblain, France

Ovarian cancer is a frequent and severe malignancy. Over 75% of cases are diagnosed at an advanced stage with disease spread beyond the ovaries. Despite the high response rates of initial treatments (i.e.,70-80%), the median progression-free survival of advanced ovarian cancer is 16-22 months, and the 5-year overall survival, 20-30%. The majority of these patients relapse, with metastatic peritoneal spread, unresectable, or drug resistant disease. Our goal was to outline current knowledge about diagnosis, prognostic factors, and treatments, and to dwell on non-nuclear medicine and nuclear-medicine diagnostic procedures.